We found that higher FERMT1 expression was significantly correlated with shorter OS in patients with NSCLC (HR = 1.28, log-rank P = 0.00013), while higher FERMT2 expression was strongly associated with better long-term OS (HR = 0.76, log-rank P = 1.4e−05) and FP (HR = 0.82, log-rank P = 0.04) (Fig. 4). Here, FERMT1 is linked to non-small cell lung carcinoma.